Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting Efficacy of PD-1 Inhibitors in Esophageal Squamous Cell Carcinoma
Summary
NIH registered an observational study (NCT07533357) examining Tpex subsets in negative tumor draining lymph nodes as predictors of PD-1 inhibitor efficacy in advanced or recurrent esophageal squamous cell carcinoma. The study aims to determine whether high proportions of precursor exhausted T cells correlate with longer overall survival and whether Tpex has better predictive efficacy for treatment response than PD-L1 CPS.
What changed
NIH registered a new observational clinical trial (NCT07533357) on ClinicalTrials.gov. The study will investigate whether patients with high proportions of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes demonstrate longer overall survival when treated with PD-1 inhibitors.
Affected parties include healthcare providers conducting oncology research and cancer patients with advanced or recurrent esophageal squamous cell carcinoma. This registry entry establishes transparency for the ongoing research but does not create compliance obligations.
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell Carcinoma
Observational NCT07533357 Kind: OBSERVATIONAL Apr 16, 2026
Abstract
The goal of this observational study is to to determine whether patients with a high proportion of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes have longer overall survival. The main question it aims to answer is: Whether precursor exhausted T cells (Tpex) in negative tumor-draining lymph nodes have better predictive efficacy for treatment response than PD-L1 CPS.
Conditions: Esophageal Cancer
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.